Cost-effectiveness analyses and utility weights
Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles.
8 cost-effectiveness analyses and 6 studies reporting utility weights · 9 sources
Overview
| Item | Detail |
|---|---|
| Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. |
| Cost-effectiveness analyses | 8 |
| Studies reporting utility weights | 6 |
Cost-effectiveness analyses
Analyses of Imsidolimab
No evidence found.
Treatments for the same indication
No evidence found.
The same disease in other populations or settings
No evidence found.
Related diseases and analogous treatments
Targeted biologics and apremilast versus no targeted treatment in moderate to severe plaque psoriasis, United States: Hendrix et al. (2018)
Relevance: Evaluates TNF, IL-17, and IL-12/23 inhibitor biologics and apremilast in moderate to severe plaque psoriasis in the United States, covering the TNF and IL-17 inhibitor classes that section 2 lists as second-line and maintenance options in generalized pustular psoriasis.
“We developed a Markov model to simulate patient outcomes as measured by quality-adjusted life-years (QALYs) and health care costs over a 10-year period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since our drugs of interest are usually reserved for patients who have failed topical drugs, phototherapy, and methotrexate, we included only targeted drugs in the model.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To allow our study to be relevant to coverage decisions, we used a payer perspective and, therefore, considered direct medical costs only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total treatment costs were summed over 10 years using a 3% annual discount rate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Wholesale acquisition drug costs were discounted by a class-specific, empirically derived rebate percentage off of 2016 costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Base-Case Estimates of Cost, QALYs, and Incremental Cost-Effectiveness with 10-Year Time Horizon” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Apremilast 137,080 6.403 81,033 (vs. no treatment)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Etanercept 181,387 6.505 433,248 (vs. apremilast)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adalimumab 194,180 6.681 72,703 (vs. etanercept)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Infliximab 176,695 6.804 Dominant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ustekinumab 255,422 6.959 Dominated” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secukinumab 208,727 7.045 132,913 (vs. infliximab)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Brodalumab 236,690 7.173 217,589 (vs. secukinumab)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ixekizumab 243,938 7.208 208,872 (vs. brodalumab)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our probabilistic sensitivity analysis indicated that apremilast and infliximab are likely to provide the most net monetary benefit at willingness-to-pay (WTP) thresholds near $100,000 (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bimekizumab, narrowband UV-B phototherapy, and step therapy in moderate to severe plaque psoriasis, United States: Kong and Buzney (2026)
Relevance: Compares bimekizumab, an IL-17 inhibitor, with home or office narrowband UV-B phototherapy and with step therapy from phototherapy to biologics in moderate to severe plaque psoriasis from a United States payer perspective, treatment classes that section 2 describes for generalized pustular psoriasis.
Access: Not open access
Not quoted: The results are reported in the full text, which is closed access.
“Simulation modeling study in patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] ≥12) using published estimates of efficacy, costs, and mappings between PASI score and quality-adjusted life-years (QALYs) from 2013 through 2025.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One year of treatment with a representative biologic (bimekizumab), narrowband UV-B phototherapy (home or office) or a step-therapy regimen where patients initiated phototherapy for 16 weeks and switched to biologics if PASI90 (an improvement in PASI score of ≥90%) was not achieved, continuing the more effective therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Main outcomes were PASI reductions at 32 weeks, QALYs monetized as $100 000 per QALY, and total treatment costs to payers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) QALY gains were 0.24 (0.08) for biologics, 0.18 (0.09) for phototherapy, and 0.23 (0.06) for step therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) annual total costs were $84 034 (0) for biologics, $14 760 (0) for office phototherapy, and $6222 (0) for home phototherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From the payer perspective, mean (SD) net willingness to pay was highest for home phototherapy ($11 694 [$9421]) and lowest for biologics (-$59 926 [$7916]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Phototherapy remained cost-effective for payers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ixekizumab every 2 weeks and etanercept versus ixekizumab every 4 weeks in moderate to severe plaque psoriasis, United States: Udkoff and Eichenfield (2017)
Relevance: Evaluates the IL-17 inhibitor ixekizumab against etanercept, a TNF inhibitor, in moderate to severe plaque psoriasis in the United States, a class section 2 lists for maintenance treatment of generalized pustular psoriasis.
“We constructed a Markov model to calculate the cost-effectiveness of etanercept and ixekizumab treatments from a limited societal perspective” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The end-point was the calculation of the incremental cost effectiveness ratios (ICER) of 12-week courses of bi-weekly etanercept, ixekizumab every 2 weeks and ixekizumab every 4 weeks over a 60-week time horizon (5 Markov cycles).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs in 2016 U.S. dollars were compared using the effectiveness of treatments as measured by the quality adjusted life years (QALY) gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We used a standard annual discount of 3.0% for both costs and QALYs per previous analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This simulation demonstrated ixekizumab every 4 weeks to have a mean cost of $79,734.18 and effectiveness of 0.857 QALY over the 60-week time horizon” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ixekizumab every 2 weeks had a mean cost of $101,108.87 with an incremental effectiveness of 0.006 and an ICER of $3,422,386.62 when compared to ixekizumab every 4 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The bi-weekly etanercept cost was $108,415.63 with a mean effectiveness of 0.825 QALY and an ICER of -$913,870.47 when compared to ixekizumab every 4 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The negative ICER in this instance is indicative of etanercept therapy being vastly more expensive and less effective than ixekizumab every 4 weeks ( dominated ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ustekinumab versus etanercept in moderate to severe plaque psoriasis, United States: Villacorta et al. (2013)
Relevance: Evaluates ustekinumab against etanercept in moderate to severe plaque psoriasis in the United States, with health states defined by psoriasis area and severity index response.
“This study evaluated the cost effectiveness of ustekinumab compared with etanercept from a US societal perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A Markov model was constructed to simulate the incremental cost per quality-adjusted life-year (QALY) gained every 12 weeks over a base-case 3-year time horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A hypothetical patient cohort was based on the characteristics of the phase III Active Comparator Psoriasis Trial (ACCEPT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were adjusted to 2011 US dollars. A 3 % annual discount rate was applied to costs and QALYs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For the base-case 3-year time horizon, the incremental cost-effectiveness ratio comparing ustekinumab 90 mg with etanercept 50 mg was US$384,401 per QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ustekinumab 45 mg dominates etanercept 50 mg for the same time horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The probabilistic sensitivity analysis suggests ustekinumab 90 mg has a minimal (4 %) chance of being cost effective compared with etanercept 50 mg at a willingness-to-pay threshold of US$150,000 per QALY improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For the same threshold, ustekinumab 45 mg has a high (88 %) chance of being cost effective compared with etanercept 50 mg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Secukinumab versus other biologics in moderate to severe plaque psoriasis, China: Zhang et al. (2023)
Relevance: Evaluates secukinumab against guselkumab, ixekizumab, ustekinumab, adalimumab, infliximab, and etanercept in moderate to severe plaque psoriasis from a Chinese healthcare system perspective, spanning the IL-17, IL-23, and TNF inhibitor classes section 2 lists for generalized pustular psoriasis.
“A decision-tree (first year)/Markov model (subsequent years), with an annual cycle, was implemented over a lifetime horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The base-case analysis assessed the cost-effectiveness of secukinumab compared with other biologics from the Chinese healthcare system perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An annual discount rate of 5% was applied to both costs and outcomes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All cost inputs were inflated to 2022 using the Chinese consumer price index (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs, QALYs, and ICER values for patients with moderate-to-severe plaque psoriasis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secukinumab ¥231,477 12.334” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adalimumab ¥284,034 12.120 Dominates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Infliximab ¥369,555 12.330 Dominates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ustekinumab ¥233,666 12.098 Dominates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ixekizumab ¥228,320 12.284 ¥62,323/QALY” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Guselkumab ¥272,709 12.202 Dominates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Yisaipu ¥254,220 11.750 Dominates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, secukinumab was a cost-effective option compared with ixekizumab at a WTP threshold of ¥257,094 per QALY gained (Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sequential IL-17 inhibitors versus methotrexate or ciclosporin in moderate to severe plaque psoriasis, Thailand: Dilokthornsakul et al. (2024)
Relevance: Evaluates IL-17 inhibitors against methotrexate or ciclosporin in moderate to severe plaque psoriasis in Thailand, comparing a biologic class with the conventional systemic agents section 2 lists for generalized pustular psoriasis.
“A cost-utility analysis was conducted from a societal perspective with a lifetime horizon. A decision tree with a Markov model was developed ( Fig 1 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with moderate-to-severe psoriasis aged 40 years old with PASI score of ≥ 15 who had an inadequate response to conventional systematic treatments were eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Methotrexate or ciclosporin was used as standard of care (SoC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All costs were inflated to the 2021 value using the consumer price index and converted to US dollar ($) using the average exchange rate in the year 2021 which was 0.0313 $/Thai baht (THB).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All analyses applied an annual discount rate of 3% for both cost and QALY” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatments Cost (THB) Life-year QALY Incremental cost (THB) Incremental cost ($) Incremental QALY ICER (THB/QALY) ICER ($/QALY)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sequence1 2,646,675 20.589 16.484 1,863,287 58,321 2.995 621,373 19,449” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sequence2 3,808,175 20.589 16.649 3,024,787 94,676 3.160 957,258 29,962” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sequence3 4,552,700 20.589 16.318 3,769,313 117,979 2.829 1,332,262 41,700” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sequence 1: Secukinumab followed by Ixekizumab/Brodalumab then Guselkumab, Sequence 2: Ixekizumab followed by Secukinumab /Brodalumab then Guselkumab, Sequence 3: Brodalumab followed by Ixekizumab/Secukinumab then Guselkumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the current willingness-to-pay of 160,000 THB/QALY, no sequential IL-17 inhibitor was cost-effective compared to SoC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Apremilast and biologics versus standard of care in moderate to severe plaque psoriasis after conventional systemic therapy, Canada: CADTH (2017)
Relevance: A Canadian health technology assessment that evaluates apremilast, TNF inhibitors, ustekinumab, and secukinumab against standard care with topical agents and phototherapy in moderate to severe plaque psoriasis.
“SUMMARY OF RESULTS OF THE MANUFACTURER’S BASE CASE” (opens the source at this quote in a new tab)
“Apremilast $24,101 5.83 $17,823 0.21 $83,480 $83,480” (opens the source at this quote in a new tab)
“Adalimumab $56,509 6.07 $50,331 0.45 $110,662” (opens the source at this quote in a new tab)
“Etanercept $57,646 6.03 $51,368 0.41 $124,066” (opens the source at this quote in a new tab)
“Ustekinumab $68,986 6.15 $62,708 0.53 $117,253” (opens the source at this quote in a new tab)
“Secukinumab $73,657 6.22 $67,379 0.60 $112,900” (opens the source at this quote in a new tab)
“Infliximab $116,042 6.23 $109,764 0.61 $179,676” (opens the source at this quote in a new tab)
Ixekizumab-first versus secukinumab-first biologic sequences in moderate to severe plaque psoriasis, United Kingdom: Johansson et al. (2018)
Relevance: Evaluates sequences of biologics beginning with ixekizumab or secukinumab and ending in best supportive care in moderate to severe plaque psoriasis in the United Kingdom, a sequencing structure a model of maintenance treatment after a generalized pustular psoriasis flare could adapt.
“A Markov model with a lifetime horizon was developed to compare the cost-effectiveness of ixekizumab and secukinumab treatment sequences: ixekizumab → ustekinumab → infliximab → best supportive care (BSC) vs secukinumab → ustekinumab → infliximab → BSC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The model used monthly cycles, and included four health states: trial period, treatment maintenance, BSC, and death.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An annual discontinuation rate of 20% was assumed for maintenance therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The ixekizumab sequence provided cost savings of £898 (£176,203 vs 177,101) [year 2015 values] and gained 0.03 more quality-adjusted life-years (QALYs: 1.45 vs 1.42) vs the secukinumab sequence over the lifetime horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Probabilistic sensitivity analysis showed an 89.8% likelihood that the ixekizumab sequence would be cost-effective at a threshold of £20,000 per QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The analysis used list prices for drugs rather than confidential, preferentially priced Patient Access Scheme costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights
Utility weights from analyses of Imsidolimab
No evidence found.
Utility weights for the same indication
No evidence found.
Utility weights for the same disease in other populations or settings
No evidence found.
Utility weights for related diseases and analogous treatments
Utility weights by PASI response and without targeted treatment, moderate to severe plaque psoriasis: Hendrix et al. (2018)
Relevance: EQ-5D utilities by psoriasis area and severity index response band and for plaque psoriasis without a targeted agent, from a United States model of psoriasis biologics.
“Utilities for the base-case scenario were obtained from an analysis of EQ-5D data in 3,231 patients enrolled in 5 randomized controlled trials evaluating secukinumab in moderate to severe plaque psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The EQ-5D was measured alongside PASI in the secukinumab trials, and the improvement in PASI score was mapped onto the EQ-5D, resulting in a utility of 0.906 for PASI 90-100, 0.868 for PASI 75-89, 0.835 for PASI 50-74, and 0.751 for PASI improvement of less than 50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The utility for patients not receiving any targeted agent was 0.642, based on this study’s estimate of its population’s baseline (i.e., untreated) utility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights by PASI response and at baseline, moderate to severe plaque psoriasis: Udkoff and Eichenfield (2017)
Relevance: EQ-5D utilities by psoriasis area and severity index response band and at baseline in moderate to severe plaque psoriasis, from a United States model.
“We converted the PASI percent improvement into health utility scores using EuroQol 5-Dimension Health Questionnaire (EQ-5D) health utility scores produced from the UNCOVER trial’s data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights by PASI response and for conventional systemic therapy, moderate to severe plaque psoriasis: Zhang et al. (2023)
Relevance: EQ-5D utilities by psoriasis area and severity index response band in moderate to severe plaque psoriasis, from a model that includes IL-17 and IL-23 inhibitors.
“An ordinal logistic regression method was implemented to map DLQI data to EQ-5D-3L-based utility estimates using the Chinese EQ-5D value set (Table 4)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disutilities associated with methotrexate and cyclosporine, and the proportion of patients using each therapy are available in Table 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights by PASI response, severe plaque psoriasis: Villacorta et al. (2013)
Relevance: Utilities by psoriasis area and severity index response in severe plaque psoriasis, from a United States model of ustekinumab against etanercept.
Access: Not open access
Not quoted: The utility weights are reported in the full text, which is closed access.
Baseline utility and utility gains by PASI response, moderate to severe plaque psoriasis: Barker et al. (2021)
Relevance: Baseline utility and incremental utility gains by psoriasis area and severity index response in moderate to severe plaque psoriasis, sourced from studies in moderate-to-severe psoriasis populations.
“Each PASI response health state was associated with a different utility in the model such that higher PASI responses were associated with greater patient quality of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Utilities were sourced from relevant studies with moderate-to-severe psoriasis populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PASI score Incremental utility gain (from baseline)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline utility weight and utility change by PASI response, moderate to severe plaque psoriasis: CADTH (2017)
Relevance: Baseline utility and utility change by psoriasis area and severity index response, based on SF-36 utilities from the apremilast trials, in moderate to severe plaque psoriasis, from a Canadian health technology assessment.
Search strategy
| Dataset | Query | Results |
|---|---|---|
| Methods | imsidolimab | 0 |
| Ratios | imsidolimab | 0 |
| Ratios | "generalized pustular psoriasis" OR "pustular psoriasis" | 0 |
| Ratios | pustular | 0 |
| Ratios | spesolimab | 0 |
| Methods | pustular OR spesolimab | 0 |
| Weights | pustular OR spesolimab | 0 |
| Ratios | psoriasis | 286 |
| Ratios | "plaque psoriasis" | 115 |
| Ratios | psoriasis AND (guselkumab OR risankizumab OR tildrakizumab) | 48 |
| Ratios | guselkumab OR risankizumab OR tildrakizumab | 50 |
| Weights | psoriasis | 115 |
| Ratios | pustulosis OR erythrodermic OR "IL-36" OR interleukin-36 | 1740 |
| Methods | pustulosis | 0 |
| Weights | "psoriasis" AND flare | 0 |